Biohaven Gets FDA Priority Review of Troriluzole

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the US Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application (NDA) for troriluzole for the treatment of adult patients with spinocerebellar ataxia (SCA) and has granted Priority Review.
Biohaven's troriluzole gains FDA priority review for SCA
NEW HAVEN, Conn. - Biohaven Ltd. (NYSE: BHVN), a biotechnology company with a market capitalization of $3.87 billion, announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for troriluzole,
Biohaven Gets FDA Priority Review of Troriluzole for Spinocerebellar Ataxia
Biohaven has won Food and Drug Administration priority review for its application seeking approval of troriluzole for adults with spinocerebellar ataxia, a group of rare, genetic neurological disorders. Biohaven on Tuesday said a green light would make troriluzole the first and only FDA-approved treatment for the life-threatening disorder.
FDA grants brensocatib priority review for bronchiectasis
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a manufacturer-issued press release.If approved, the release said this will be the first treatment for this patient population.
Biohaven’s troriluzole NDA in spinocerebellar ataxia accepted by the FDA
Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of
Biohaven stock rises following FDA review and Deutsche Bank's buy rating
Shares of Biohaven Ltd. (NYSE: BHVN) climbed 7% as the company announced the FDA's acceptance and Priority Review of its ...
Seeking Alpha4d
Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity
Brensocatib, Insmed's lead pipeline candidate for non-CF bronchiectasis, received FDA Priority Review with a target action date of August 12, 2025. This is a potential multi-billion dollar selling ...
Monthly Prescribing Reference14d
Novel Therapy for Pyruvate Dehydrogenase Complex Deficiency Gets Priority Review
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex ...
Morningstar21d
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of July 22, 2025. The FDA also informed the Company that they are not currently planning to hold ...
Trump's Crypto Czar Says Strategic Bitcoin Reserve Review A Priority, But $BTC Unmoved
David Sacks had very bullish statements around Bitcoin and crypto in his first ever media briefing as he confirmed that ...
Biohaven Ltd.: Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression ...